New Breast Cancer Drug Fails Cost-Effectiveness Tests in US and China
A new economic evaluation finds that datopotamab deruxtecan is not cost-effective compared with chemotherapy for advanced triple-negative breast cancer in ...
A new economic evaluation finds that datopotamab deruxtecan is not cost-effective compared with chemotherapy for advanced triple-negative breast cancer in ...
A retrospective cohort study found amphotericin B liposome demonstrated fewer infusion reactions than cholesterol sulfate, while showing comparable overall efficacy ...
A study of 133 oncology reimbursement reports in five European countries found no consistent link between added therapeutic value and ...
A decision-tree modeling study reveals that long-acting reversible contraception, especially the copper intrauterine device, provides significantly greater cost-effectiveness and clinical ...
A systematic multi-dimensional evaluation of ten injectable neuroprotective agents for acute ischemic stroke found that only butylphthalide and sodium chloride ...
A partitioned survival model indicates that daraxonrasib improves survival outcomes in metastatic pancreatic ductal adenocarcinoma but requires major price reductions ...
A scoping review reveals frequent measure-to-pathway mismatches in pharmacoeconomic stroke prevention models and proposes a structured pre-model audit framework.
An observational economic analysis of the NIH All of Us Research Program found that third-line immunotherapy for advanced colorectal cancer ...
A model-based pharmacoeconomic evaluation finds that probiotics are not cost-effective for gestational diabetes mellitus in China compared to placebo.
A pharmacoeconomic analysis using Asian cohort data from the INAVO120 trial finds that inavolisib plus palbociclib/fulvestrant is not cost-effective nationally ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine